Skip to main content
logo
Acumen Pharmaceuticals, Inc. (ABOS)
NASDAQ: ABOS · Real-Time Price · USD
3.100
+0.025 (0.81%)
At close: Aug 25, 2026, 4:00 PM EDT
3.030
-0.070 (-2.26%)
After-hours: Aug 25, 2026, 7:59 PM EDT

Acumen Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cost of Revenue
86.79104.8993.842.3232.3612.31
Gross Profit
-86.79-104.89-93.8-42.32-32.36-12.31
Selling, General & Admin
18.6318.9520.2218.8212.887.28
Operating Expenses
18.6318.9520.2218.8212.887.28
Operating Income
-105.42-123.83-114.02-61.14-45.24-19.58
Interest Expense
-4.32-4.22-4.07-0.58--
Interest & Investment Income
5.147.4514.3210.792.390.24
Other Non Operating Income (Expenses)
-0.45-0.731.44-1.44-0.01-81.11
EBT Excluding Unusual Items
-105.04-121.34-102.33-52.37-42.86-100.45
Gain (Loss) on Sale of Investments
------0.16
Pretax Income
-105.04-121.34-102.33-52.37-42.86-100.61
Net Income
-105.04-121.34-102.33-52.37-42.86-100.61
Net Income to Common
-105.04-121.34-102.33-52.37-42.86-100.61
Net Income Growth
------
Shares Outstanding (Basic)
646160494120
Shares Outstanding (Diluted)
646160494120
Shares Change
6.39%0.91%23.46%19.72%102.43%4685.59%
EPS (Basic)
-1.64-2.00-1.71-1.08-1.06-5.02
EPS (Diluted)
-1.64-2.00-1.71-1.08-1.06-5.02
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-91.79-115.63-86.23-43.09-35.31-18
Free Cash Flow Per Share
-1.43-1.91-1.44-0.89-0.87-0.90
EBITDA
-105.37-123.77-113.95-61.08-45.21-19.58
D&A For EBITDA
0.050.060.060.060.030
EBIT
-105.42-123.83-114.02-61.14-45.24-19.58
SEC Filings: 10-K · 10-Q